NuVasive on Aug. 2 posted $317.8 million in second quarter sales ahead of its merger with Globus Medical.
Four things to know:
1. Second quarter sales grew 2.4 percent year-over-year. For the first half of 2023, sales were $625.5 million.
2. NuVasive saw a net income of $7.4 million in the second quarter.
3. Revenue was primarily driven by increased product adoption and increased surgical volumes in the U.S.
4. The company is maintaining its full-year growth projection of 6 percent to 8 percent revenue increases compared to 2022.